NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Nuvation Bio Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.48+0.03 (+0.67%)
Close on Oct 19, 2026
- Market cap
- $1.56M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.07 (+31.38%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Nuvation Bio Inc. grew revenue 1083.6% to $169.90M over the twelve months to Jun 30, 2026.
Revenue
$169.90M
+1083.6% vs. a year earlier
Operating income
-$137.63M
TTM Q2 2026
EPS, diluted
-$0.60
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.56M
- P/E ratio
- –
- Price to sales
- 0.01
- Price to book
- 0.01
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $169.90M
- Net income
- -$149.83M
- EPS, diluted
- -$0.60
- Book value per share
- $727.88
- Diluted shares
- 0M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$169.90M+1083.6% YoY
Gross profit
–
Operating income
-$137.63M
Net income
-$149.83M
EPS, diluted
–
Reported periodTrailing twelve months